Application of Intelligent Care Systems in Radiation Therapy: Enhancing Patient Safety and Reducing Anxiety Through System Optimization, Enhanced Education Strategies, and Real-Time Blood Data Monitoring

This study aims to evaluate the impact of an intelligent care system on radiation therapy patients, focusing on real-time blood data monitoring, optimized patient education, and internal alert systems. The goal is to enhance patient safety, improve treatment adherence, and reduce anxiety by integrating an alert function into the hospital's existing system.
Key interventions include:
Real-time blood monitoring alerts: Healthcare providers will receive automatic notifications of abnormal blood test results to ensure timely intervention.
Optimized patient education materials: Clearer guidance will help patients proactively communicate blood test needs and manage their health during radiation therapy.
Internal reminders: Visual signs and alerts in treatment areas will reinforce patient awareness and engagement.
The study will compare patients receiving these interventions with those under standard care, assessing treatment compliance, anxiety levels, and clinical outcomes over a 12-month period.

Start Date20 Feb 2025

Sponsor / Collaborator

Chung Shan Medical University

NCT06658821

/ Not yet recruitingNot ApplicableIIT

The Effect of LDL557 on Improving Degenerative Arthritis in the Elderly

This project is to conduct a clinical trial of SYNBIO TECH INC.'s LDL557 capsule for joint protection. To understand the improvement of joint discomfort and inflammation after supplementation, we hope to provide an updated choice for modern people's joint protection.

Start Date01 Dec 2024

Sponsor / Collaborator

Chung Shan Medical University

NCT06620328

/ Not yet recruitingNot ApplicableIIT

Safety and Efficacy of Mechanical Versus Electrocautery Dilator for EUS-guided Biliary Drainage: A Prospective Randomized Controlled Trial

The purpose of this study is to investigate the likelihood of post-dilation bleeding using mechanical or electrocautery dilation. We hypothesized that the risk of bleeding is lower in the mechanical group.

Start Date01 Oct 2024

Sponsor / Collaborator

National Taiwan University Hospital

[+9]

100 Clinical Results associated with Chung Shan Medical University

0 Patents (Medical) associated with Chung Shan Medical University

12,184

Literatures (Medical) associated with Chung Shan Medical University

31 Dec 2025·Hematology

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis

Review

Author: Lin, Cheng-Hsien ; Teng, Chieh-Lin Jerry ; Su, Yu-Chen ; Wang, Yin-Che

BACKGROUNDThe current study aimed to compare treatment responses, the incidence of the need for auto-HSCT, and the occurrence of specific adverse events (AEs) between VTD and velcade, VRD induction regimens in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM).METHODSThis systematic review and meta-analysis included 15 studies: six evaluating the VTD regimen and nine evaluating the VRD one. The primary endpoints were response rates after induction therapy and the incidence of a need for autologous hematopoietic stem cell transplantion (auto-HSCT) between the groups. We also examined the occurrence of grade 3 or 4 hematological, infection, and thrombotic AEs in both groups.RESULTSThe VTD group showed an overall response rate (ORR) of 93%, while the VRD group had an ORR of 86%. The very good partial response (VGPR) rates were 61% in the VTD group and 60% in the VRD one. The auto-HSCT rate was higher in the VTD group, averaging 93% compared to 70% in the VRD one. The incidence of grade 3 or 4 hematological AEs was 31% for VTD and 33% for VRD. The rates of grade 3 or 4 infection-related AEs were 9% in the VTD group and 14% in the VRD one. The incidence of grade 3 or 4 thrombotic AEs was 4% for VTD and 3% for VRD.CONCLUSIONSWith comparable safety profiles, VTD and VRD induction therapies are similarly effective for transplant-eligible NDMM, showing similar ORRs and VGPR rates.

31 Dec 2025·International Journal of Hyperthermia

Thermal ablation included in multimodality treatment predicts enhanced survival in advanced non-small cell lung cancer: a propensity score-matched outcome study

Author: Ku, Yueh-Han ; Hsiao, Tzu-Hsuan ; Lin, Frank Cheau-Feng ; Chen, Yi-Min ; Tsai, Stella Chin-Shaw ; Wu, Tzu-Chin ; Liao, Pin-Hsu ; Hsu, Chia-Hsuan

31 Dec 2025·Channels

Biophysical and structural mechanisms of epilepsy-associated mutations in the S4-S5 Linker of KCNQ2 channels

Article

Author: Yang, Yen-Yu ; Chang, Hsueh-Kai ; Yang, Shi-Bing ; Wong, Swee-Hee ; Lee, Inn-Chi

Mutations in KCNQ2 are linked to various neurological disorders, including neonatal-onset epilepsy. The severity of these conditions often correlates with the mutation's location and the biochemical properties of the altered amino acid side chains. Two mutations affecting aspartate at position 212 (D212) in the S4-S5 linker of KCNQ2 have been identified. Interestingly, while the charge-conserved D212E mutation leads to severe neonatal-onset developmental and epileptic encephalopathy (DEE), the more dramatic substitution to glycine (D212G) results in self-limited familial neonatal epilepsy (SLFNE), a much milder pathology. To elucidate the underlying mechanisms, we performed electrophysiological studies and in silico simulations to investigate these mutations' biophysical and structural effects. Our findings reveal that the D212E mutation stabilizes the channel in the voltage sensor down-state and destabilizes the up-state, leading to a rightward shift in the voltage-dependent activation curve, slower activation kinetics, and accelerated deactivation kinetics. This disruption in KCNQ2 voltage sensitivity persists even in the more physiologically relevant KCNQ2/3 heterotetrameric channels. In contrast, the D212G mutation primarily destabilizes the up-state, but its impact on voltage sensitivity is significantly reduced in KCNQ2/3 heterotetrameric channels. These findings provide key insights into the biophysical and structural basis of KCNQ2 D212 mutations and their contribution to epilepsy-related symptoms, offering a clearer understanding of how these mutations drive the varied clinical outcomes observed in patients.

News (Medical) associated with Chung Shan Medical University

15 Mar 2024

·www.healthcareitnews.com

Gleneagles Hospital zeroes in on radiology AI and more briefs

Gleneagles Hospital, part of the international private hospital group IHH Healthcare, has partnered with medical AI providers to bolster its diagnostics capability in Singapore and Hong Kong. On one hand, the radiology department at Gleneagles Hong Kong will be adopting Australian company Annalise.ai's AI solution for analysing chest X-rays and CT brain scans Gleneagles Singapore, on the other hand, will be integrating South Korean company Lunit's AI-powered mammography analysis solution, Lunit INSIGHT MMG, into its breast screening workflow. Taiwan looks to validate Lunit's AI for its national cancer screening Alongside the Gleneagles contract, Lunit will also be providing its chest X-ray software, Lunit INSIGHT CXR, to Chung Shan Medical University in Taiwan. The solution is intended to be validated for potential integration into Taiwan's national cancer screening program. Ex-Bitsmedia CEO joins Doctor Anywhere Doctor Anywhere, a telemedicine provider in Southeast Asia, has recently announced the appointment of Louis-Bernard Carcouet as its VP of Product. Carcouet was the former CEO of Bitsmedia, the company behind the Muslim lifestyle app, Muslim Pro. He was also previously with Asia-focused property portal, PropertyGuru, as product manager. Based on a press statement, Carcouet will lead DA's product strategy, focusing on improving user experience across platforms. "Louis’ long history of product innovation and leadership in the tech industry, coupled with his passion for improving healthcare, make him an invaluable addition to the DA team," DA founder and CEO Lim Wai Mun said about his appointment. "We’ve seen how technology has been a catalyst for healthcare, in enhancing patient experiences and driving positive outcomes. With a relentless focus on user-centric design and innovation, I’m excited to collaborate with our team to build products that truly make a difference in people’s lives," Carcouet also commented.

Executive Change

12 Mar 2024

·www.nsmedicaldevices.com

Lunit expands AI medical imaging solutions in Taiwan and Singapore

Lunit will provide its AI-powered INSIGHT CXR solution for the detection of chest abnormalities to the Chung Shan Medical University in Taiwan, and INSIGHT MMG solution for mammography analysis, to the Gleneagles Hospital in Singapore Lunit’s AI-powered chest X-ray analysis solution INSIGHT CXR. (Credit: PRNewswire/ Lunit) Medical AI company Lunit has teamed up with the Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore, expanding into the East and Southeast Asian regions. Under the partnership, Lunit will supply its INSIGHT CXR solution for the detection of chest abnormalities to Chung Shan Medical University in Taiwan. The medical device maker will also provide its INSIGHT MMG solution for mammography analysis, to the Gleneagles Hospital in Singapore. Lunit CEO Brandon Suh said: “As demand for cutting-edge medical services continues to rise across East and Southeast Asia, Lunit is proud to spearhead the advancement of AI-powered solutions for cancer diagnostics in the region. “Our strategic partnerships with Chung Shan Medical University and Gleneagles Hospital Singapore strengthen our presence and open new opportunities across the market. “We believe that these contracts will pave the way for innovative approaches to cancer detection, ultimately improving patient outcomes in areas where they are most crucial.” Through the partnership with Chung Shan Medical University (CSMU), Lunit will modernise Taiwan’s national lung cancer screening programme, which currently depends on low‐dose computed tomography (LDCT) in high-risk individuals. CSMU will validate Lunit’s INSIGHT CXR solution for potential integration into the national cancer screening programme. The university will evaluate its ability to detect individuals more accurately and effectively, expanding the screening to a wider group beyond high-risk individuals. Also, Lunit will deliver its AI-powered mammography analysis solution INSIGHT MMG to Gleneagles Hospital in Singapore, a private healthcare facility within the IHH group. By integrating Lunit’s advanced technology into its breast screening workflow, the hospital aims to enhance its screening accuracy and operational efficiency. Earlier this year, Lunit signed a three-year supply contract with Samsung Electronics (Samsung Healthcare), to integrate its AI technology into Samsung’s premium X-ray devices. Under the partnership, Lunit will provide Samsung Electronics with two of its AI-powered chest screening solutions, Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage.

11 Mar 2024

·www.prnewswire.com

Lunit Expands AI Medical Imaging Solutions in East & Southeast Asia: Partners with Chung Shan Medical University and Gleneagles Hospital Singapore

AI-powered Lunit INSIGHT CXR and Lunit INSIGHT MMG to enhance lung and breast cancer detection in Taiwan and Singapore SEOUL, South Korea, March 11, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced two supply contracts that mark its strategic expansion into the East and Southeast Asian region. Lunit will supply its Lunit INSIGHT CXR for chest abnormality detection and Lunit INSIGHT MMG for mammography analysis to the Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore, respectively. Chung Shan Medical University to Pioneer AI in Lung Cancer Detection Continue Reading (from left to right) Lunit's AI-powered chest X-ray analysis solution "Lunit INSIGHT CXR" and Lunit's AI solution for mammography analysis "Lunit INSIGHT MMG" Under the newly inked supply contract, Lunit will collaborate with the prestigious Chung Shan Medical University (CSMU), Taiwan's leading medical university. This collaboration holds the potential to revolutionize Taiwan's national lung cancer screening program. Compared to Taiwan's current screening program, which relies on low‐dose computed tomography (LDCT) for screening high-risk individuals such as smokers or those with a family history of lung cancer, CSMU aims to validate Lunit INSIGHT CXR for potential integration into the national cancer screening program. The goal is to assess its ability to detect individuals more accurately and efficiently, potentially expanding the screening to a broader group beyond high-risk individuals. This approach could significantly advance Taiwan's efforts to enhance early detection and improve outcomes in lung cancer screening. Gleneagles Hospital Singapore Chooses Lunit for Enhanced Breast Cancer Screening In a parallel move, Lunit is set to deliver its AI-powered mammography analysis solution, Lunit INSIGHT MMG, to Gleneagles Hospital in Singapore, a prominent private healthcare facility within the IHH group. Gleneagles plans to enhance screening accuracy and operational efficiency by seamlessly integrating Lunit's cutting-edge technology into its breast screening workflow. Gleneagles Hospital, part of Southeast Asia's largest medical group, IHH, is a leading private healthcare provider in the region. Recognized with the Singapore Quality Class certification, the hospital offers extensive clinical facilities with 221 beds, emphasizing its commitment to exceptional standards in healthcare. "As demand for cutting-edge medical services continues to rise across East and Southeast Asia, Lunit is proud to spearhead the advancement of AI-powered solutions for cancer diagnostics in the region," said Brandon Suh, CEO of Lunit. "Our strategic partnerships with Chung Shan Medical University and Gleneagles Hospital Singapore strengthen our presence and open new opportunities across the market. We believe that these contracts will pave the way for innovative approaches to cancer detection, ultimately improving patient outcomes in areas where they are most crucial." About Lunit Founded in 2013, Lunit is a deep learning-based medical AI company on a mission to conquer cancer. We are committed to harnessing AI to ensure accurate diagnosis and optimal treatment for each cancer patient using AI-powered medical image analytics and AI biomarkers. As a medical AI company grounded on clinical evidence, our findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and the Lancet Digital Health, and global conferences, including ASCO and RSNA. After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically used in approximately 3,000+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide. For more information, please visit lunit.io. SOURCE Lunit

100 Deals associated with Chung Shan Medical University

100 Translational Medicine associated with Chung Shan Medical University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 07 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Isoquercetin	Lung Injury More	Preclinical
CHS-111 ( Akt x PAK1 x PKC )	-	Pending
Jing Ceih Shern Yuan Extract Pill	Osteoarthritis, Hip More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis